Clinical Trial

OCT-Guided Stent Optimization for Short-Duration Dual Antiplatelet Therapy in Stable Angina

Study acronym: COMFORT-SHORT
Recruiting
View on ClinicalTrials.gov →
Summary
This study aims to evaluate whether the use of optical coherence tomography (OCT), an advanced intravascular imaging tool, can improve stent implantation results and make it possible to shorten the duration of dual antiplatelet therapy (DAPT) in patients with stable angina who undergo percutaneous coronary intervention (PCI). PCI with drug-eluting stents is a standard treatment for patients with stable angina, and these patients are usually prescribed DAPT for 6 to 12 months to prevent stent thrombosis and other complications. However, extended use of DAPT increases the risk of bleeding, which can lead to significant medical problems, especially in patients with high bleeding risk. OCT provides detailed, high-resolution images of the coronary arteries and the implanted stents, allowing physicians to optimize stent expansion and positioning. By ensuring that the stent is well-placed and fully expanded, OCT guidance may lower the risk of complications, potentially reducing the need for prolonged DAPT. In this prospective study, patients with stable angina who require stent implantation will be enrolled and treated with OCT-guided PCI followed by a short course of DAPT. Their outcomes will be compared with those managed using conventional strategies. The primary goal of this trial is to determine whether OCT-guided stent optimization can safely support a short-duration DAPT strategy, thereby reducing bleeding risk without compromising protection against ischemic events such as restenosis, myocardial infarction, or stent thrombosis.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-09-28.
Status change: Not Yet Recruiting → Recruiting 2025-12-11
Trial Details
NCT Number NCT07198529
Lead Sponsor Korea University Guro Hospital
Collaborators: Abbott
Conditions Stable Angina, Coronary Artery Disease
Enrollment 130 participants
Start Date 2025-09-30
Primary Completion 2029-09 (estimated)
Study Completion 2029-09 (estimated)
Updated on ClinicalTrials.gov 2025-12-17